AMC Group Chairman, University of California, LA

AMC 集团董事长，加州大学洛杉矶分校

基本信息

批准号：
8426568
负责人：
RONALD T. MITSUYASU
金额：
$ 4.09万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8426568
关键词：
AIDS Malignancy Consortium AIDS clinical trial group Accountability Acquired Immunodeficiency Syndrome Address Adolescent Africa African Area Arkansas Biological Markers Biology California Cancer Trials Support Unit Chairperson Cities Clinical Clinical Data Clinical Trials Clinical Trials Cooperative Group Clinical Trials Network Communities Country Decision Making Development Developmental Therapeutics Program Disease Eastern Cooperative Oncology Group Education and Outreach Enrollment Epidemic Evaluation Genetic Grant HIV Human Papillomavirus Immunologics Instruction International Intervention Kaposi Sarcoma Laboratories Leadership Lymphoma Malignant Neoplasms Mission Morbidity - disease rate National Cancer Institute National Institute of Allergy and Infectious Disease National Institute of Child Health and Human Development Oncology Group Pathologic Pathology Patients Pharmaceutical Preparations Pharmacology Population Prevention Process Protocols documentation Publications Research Research Infrastructure Research Personnel Research Training Resources Sampling Science Site Southwest Oncology Group Staging Strategic Planning Structure Supervision Testing Translational Research Universities Work authority cancer prevention cancer specimen resource cancer therapy data management improved mortality oncology operation protocol development standard of care statistical center tumor virology working group

项目摘要

Ttie AIDS Malignancy Consortium (AMC) was established in 1995 to evaluate clinical inten/entions for the treatment and prevention of malignancies in HIV and to investigate the biology of malignancies in the context of Clinical trials. Since then, the AMC has conducted 31 clinical trials involving 1934 patients with primarily HIV related malignancies, 991 (51%) enrolled since the beginning ofthe current grant cycle in 2006. Twelve studies are currently enrolling patients or are in late stages of protocol development. Several key scientific findings have emerged from AMC studies that have led to improvements in the treatment or management of patients and has helped establish the current standard of care in some cases. The group has more than doubled the number of its publication in the current cycle compared to its first 10 years. In addition, the AMC has initiated a process to include subjects with HIV-associated cancers in resource poor countries where the epidemic of HIV and cancer has grown substantially. The participation of many of the key clinical and laboratory researchers in AIDS malignancies in the USA has made the AMC the principal clinical trials group in the world dedicated to improving the treatment and prevention of cancers in this population. The scientific work ofthe group is focused in 4 disease-specific and one laboratory working groups; Kaposi's sarcoma, Lymphoma, Human Papillomavirus, Non-AIDS defining Cancers (NADC), and Laboratory and Translational Sciences Working Groups. In addition 3 resources committees support the work ofthe group; International, Outreach, Education and Recruitment and Laboratory (which oversees core labs in pharmacology, pathology, virology, biomarkers and developmental therapeutics). An Operations and Data Management Center (ODMC) at The EMMES Corporation, a Statistical Center at the University of Arkansas, and the Group Chair's Office at UCLA also support the AMC. Decision making authority is vested in the Group Chair and the Executive Committee (EC) with the Steering Committee providing scientific input and advice to the EC. The AMC consists of 8 core sites (including 3 combined city units) and 16 affiliated domestic sites. We are also in the process of establishing a network of international sites in resource-poor countries of Africa.

TTIE AIDS恶性财团（AMC）于1995年成立，以评估治疗和预防HIV中的恶性肿瘤，并在上下文中调查恶性肿瘤的生物学临床试验。从那以后，AMC进行了31项临床试验，涉及1934年的患者自2006年当前赠款周期开始以来，艾滋病毒相关的恶性肿瘤，991（51％）。十二目前，研究正在招募患者或处于协议开发的晚期。几个关键科学 AMC研究的发现已导致治疗或管理的改善在某些情况下，患者并有助于建立当前的护理标准。该小组有超过与最初的10年相比，当前周期中其出版物的数量增加了一倍。另外，AMC 已经启动了一个程序，将在资源贫困国家中包括与艾滋病毒相关的癌症的受试者艾滋病毒和癌症的流行已经大大增加。许多关键临床和美国艾滋病恶性肿瘤的实验室研究人员使AMC成为主要临床试验小组在全世界致力于改善该人群中癌症的治疗和预防。科学该小组的工作集中在4个疾病特异性和一个实验室工作组中；卡波西的肉瘤，淋巴瘤，人乳头瘤病毒，定义癌症（NADC）以及实验室和翻译科学工作组。另外，三个资源委员会支持该集团的工作；国际的，外展，教育和招聘和实验室（负责监督药理学的核心实验室，病理学，病毒学，生物标志物和发育疗法）。操作和数据管理 Emmes Corporation中心（ODMC），阿肯色大学的统计中心和加州大学洛杉矶分校的小组主席办公室也支持AMC。决策授权归属于小组主席指导委员会执行委员会（EC）为科学意见和建议 EC。 AMC由8个核心站点（包括3个联合城市单位）和16个附属的国内遗址组成。我们还在在非洲资源贫乏国家建立国际网站网络。